Clinical trial end points for high-grade glioma: the evolving landscape. - Wikidata - wikimedia - TriplyDB

Clinical trial end points for high-grade glioma: the evolving landscape.

Clinical trial end points for high-grade glioma: the evolving landscape.

http://www.wikidata.org/entity/Q37839482

about

The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Virtual Raters for Reproducible and Objective Assessments in Radiology Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients.Pros and cons of current brain tumor imaging Oleanolic acid suppresses migration and invasion of malignant glioma cells by inactivating MAPK/ERK signaling pathway Chemotherapy-related changes in cognitive functioning.Dysregulation of Fra1 expression by Wnt/β-catenin signalling promotes glioma aggressiveness through epithelial-mesenchymal transition.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview.Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.CNS Anticancer Drug Discovery and Development Conference White Paper.Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.Standards of care for treatment of recurrent glioblastoma--are we there yet?Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.Glioblastoma multiforme therapy and mechanisms of resistance.Chemotherapy-related cognitive dysfunction.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.Relationship between cognitive function and prognosis in glioblastoma.Chemotherapy in glioma.Use of bevacizumab in recurrent glioblastoma.Alpinetin targets glioma stem cells by suppressing Notch pathway.Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.Use of positron emission tomography scanning to evaluate pseudoresponse.AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.Visual field changes as an early indicator of glioblastoma multiforme progression: two cases of functional vision changes before MRI detection.Assessment of intra-observer variability in measurement of high-grade brain tumors.MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth.Semiautomated volumetric measurement on postcontrast MR imaging for analysis of recurrent and residual disease in glioblastoma multiforme.Response Assessment in Neuro-Oncology Clinical Trials.Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.

P2860

Q26829663-4C5824D1-8809-4AF7-9C7E-35A985CFD75E Q26853516-111167F6-E08A-4F73-A39A-EECD4321B34A Q27318743-44F988E4-B1A4-4BDA-B707-BE592B1BC434 Q30356126-C7892466-C19F-4946-9E40-A511623E7529 Q30607148-416ADE34-28D8-4590-956B-41BF0888D681 Q30840511-727F91D6-39B1-4C4D-83D4-24FD4F10582E Q30860126-D3239A7A-1094-445B-875A-1B9452A5CBAD Q31132303-323EA490-F699-49D8-BD11-6128C1BF2C68 Q33697950-3C4A429E-F5A6-47D7-A617-C79E42FAAF0A Q33792688-270B739F-5459-43D0-8865-6C9DA2CD3979 Q34293163-822E8EF7-2C0B-4BF9-821B-346778D06631 Q34409620-83EDABF0-1A2A-4BE4-BA97-412DDCA0F10E Q35914535-CC54191B-9BB0-484B-83F0-CCDBEB4E34C2 Q36089590-4319FC63-8E4E-4DF9-AFE8-779B68386264 Q36427538-B5113ECE-EA8E-4CAD-AF01-084530FFA898 Q36500401-D3815847-0A45-4928-AF48-493B43BEF365 Q36698172-EDDD4B23-93D7-4D2E-BCCB-261EFDE8DD0D Q36787777-198FC730-673F-43D8-8474-FC5111BE1601 Q37132708-79AA8635-1BB9-4D32-B69A-4EC32322CDDA Q37187715-0FA44610-7DE7-4733-A414-507ED3111B7F Q37415954-BB91E68E-D155-4175-95CD-C20902B6D457 Q37997653-C5B1EC12-CE7F-450C-A94B-AF0D326C47B2 Q38020234-BABDF507-B587-4299-85DD-C8BA30961F5C Q38021521-31068271-D587-4BCF-B531-589A183430FF Q38062793-A1075BD7-037D-4DF3-B89F-FB40B4DFF352 Q38068203-55B6BEB3-43AD-4A3D-9B00-DB761CC5FC86 Q38233450-6EFDD1FE-83D8-4E77-8DAD-4195EC38E66F Q38438439-BD86652E-79E6-47BE-9FCF-A03771101AE7 Q38438668-D92FD84E-70F6-4766-8369-073AC4FE9891 Q38803548-04406B9C-A592-4DBE-975A-A47F129BA4A2 Q38973191-94996A76-EC9E-4FBE-8186-5213BA60A7A7 Q39310354-145CD16C-6EF9-48F9-8120-47B097225C98 Q40033152-F47AF803-CBBA-4C9F-A4EE-C15D02C8A5A4 Q41139015-AB2CEE1E-A17F-4BEF-B90E-90B8B8AD073A Q42429881-7C999EB6-8648-4104-B66E-CA62D21CEC31 Q43932540-AD83715E-E1AE-440E-910E-E603ECA2F0DE Q44522644-1F4B9CBA-CB9A-4A3B-845F-A95176DDA480 Q45124040-C1651E1C-B74C-4A64-8180-DB32BBDA8558 Q45945655-C5FCC72B-CD11-466E-9D35-3AAAA58ED822 Q47436703-89522A6E-6BB3-4BC6-AEA9-1C570B6F3F88

P2860

Clinical trial end points for high-grade glioma: the evolving landscape.

http://www.wikidata.org/entity/Q37839482

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical trial end points for high-grade glioma: the evolving landscape.

@en

Clinical trial end points for high-grade glioma: the evolving landscape.

@nl

type

label

Clinical trial end points for high-grade glioma: the evolving landscape.

@en

Clinical trial end points for high-grade glioma: the evolving landscape.

@nl

prefLabel

Clinical trial end points for high-grade glioma: the evolving landscape.

@en

Clinical trial end points for high-grade glioma: the evolving landscape.

@nl

P1433

Q37839482-A6C70447-9FF8-4F7C-A3A3-D37FB708CF1B

P1476

Q37839482-14CC3488-E872-4370-A609-B5F98D38EB26

P2093

Q37839482-239A650E-D3FD-4789-8454-17BEA42C0143

Q37839482-54A9490A-ED97-4759-9EA0-E416354AAB88

Q37839482-5563B633-88EF-4AAC-9714-17C8D8C1ED4F

Q37839482-7F50E3D8-69D2-4724-862D-F9774336E705

Q37839482-90497855-44E7-4726-A5B7-FF840066A8C3

Q37839482-932C5297-E2EF-471A-8F0B-0D8E776A31F3

Q37839482-9669920E-B14C-4951-9A17-08AAF2D4FE37

Q37839482-B6E33B15-496B-468F-9D75-C73FF6B429AB

Q37839482-C0C5DE81-4318-457C-8170-F88CFCF562FE

Q37839482-D0C9AD7C-B83C-4F48-ACA1-EAA8549D970A

P2860

Q37839482-01AFD3B8-341A-4F65-A493-ED3216BD15CA

Q37839482-084289B4-C718-4F20-B52F-F181A896BE5C

Q37839482-0F8CB7FC-0920-4313-9C32-572C3B25E63B

Q37839482-10F1304B-8D08-4C98-AB0B-90ECE79A1987

Q37839482-1853BD4A-9CE7-4788-93D4-E54C7C67435D

Q37839482-1AE2A29E-3D93-4AC4-82C1-C770173ABF6C

Q37839482-1B5F1173-867F-415A-AC0E-8807DDDA0261

Q37839482-1C07770C-16D2-4ABC-A35A-3BFCF24AA0E4

Q37839482-22FB187F-4042-4863-BD2C-5127AF1B141E

Q37839482-26296B2A-081C-42B4-B786-0FFC3D8AB32C

P304

Q37839482-115FDEE4-27DA-44FF-9104-333999BA6911

P31

Q37839482-A4BDFD3B-A77E-4EAE-A14D-4F9A4641AD07

P356

Q37839482-D6F7643D-66E7-4DEB-81E4-D8EA0809F286

P433

Q37839482-A4752E3A-CEFA-4B7D-9B17-CD12BB10CF5A

P478

Q37839482-1EB5D2FD-9E75-4ED7-B32F-BB3C20B1573E

P50

Q37839482-1AF529D5-5833-41C1-AF83-7C2B6D23ADFA

Q37839482-81246C7B-8512-4CAE-8138-770AE83A056E

Q37839482-AF54F8E7-701E-4EA5-AAC1-6EDF0197DB22

Q37839482-ED0E7B86-6C68-4F9A-B72D-4A017D4D6AC5

P577

Q37839482-68893A20-7C5F-4D06-9B76-E9421F9B899A

P5875

Q37839482-B723C5DC-13E9-439A-BAC9-012DD3CCEA82

P698

Q37839482-A706F482-0C78-4D26-ACF4-6B25CF6B9217

P932

Q37839482-061916EA-E5D0-4FE1-BE8E-405BD920FFDF

P356

P1433

P1476

Clinical trial end points for high-grade glioma: the evolving landscape

@en

P2093

Andrew B Lassman

http://www.w3.org/2001/XMLSchema#string

David A Reardon

http://www.w3.org/2001/XMLSchema#string

David R Macdonald

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Wefel

http://www.w3.org/2001/XMLSchema#string

John F DeGroot

http://www.w3.org/2001/XMLSchema#string

Kathleen R Lamborn

http://www.w3.org/2001/XMLSchema#string

Marc C Chamberlain

http://www.w3.org/2001/XMLSchema#string

Mark R Gilbert

http://www.w3.org/2001/XMLSchema#string

Michael A Vogelbaum

http://www.w3.org/2001/XMLSchema#string

Patrick Y Wen

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.

Prognostic factors for anaplastic astrocytomas.

Clinical applications of PET in brain tumors.

P304

353-361

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ203

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Martin J van den Bent

Evanthia Galanis

P577

2011-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49826293

http://www.w3.org/2001/XMLSchema#string

P698

21310734

http://www.w3.org/2001/XMLSchema#string

P932

3064608

http://www.w3.org/2001/XMLSchema#string